Diagnostic Criteria (Adapted from consensus guidelines): Chronic multisystem symptoms consistent with mast cell activation Evidence of elevated mast cell mediators (during flare or baseline), such as: Serum tryptase Plasma histamine Chromogranin A Urinary N-methylhistamine Urinary prostaglandin D2 or F2 Improvement with medications that block mast cell activity (e.g., antihistamines, cromolyn sodium) Testing is most accurate when done during or soon after a flare , and samples often need to be chilled and analyzed at specialized labs
Human thyroid C-cells appear to express GLP-1 receptors at lower levels than rodent C-cells, suggesting that humans may be less susceptible to GLP-1-mediated thyroid proliferation, though evidence on receptor expression varies
The first late-stage trial of a GLP-1 drug in young children with obesity showed the treatment helped lower body mass index
These RWS, that are not intended to question the efficacy of drugs as determined in RCTs, have however allowed highlighting relevant pieces of information with implications from clinical points of view
Health-care professionals, eager to support their patients diagnosed with diabetes or obesity, are writing more prescriptions for these life-changing medications
Studied for stimulating collagen, elastin and glycosaminoglycan synthesis